Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists’ arsenal

References

• QuirkeVGaudillièreJPThe era of biomedicine: science, medicine, and public health in Britain and France after the Second World WarMed Hist200852444145218958248
   PubMed Web of Science ®Google Scholar
• BernhardEJBrunnerTBProgress towards the use of HIV protease inhibitors in cancer therapyCancer Biol Ther20087563663718421253
   PubMed Web of Science ®Google Scholar
• KastREBoockvarJABrüningAA conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareOncotarget20134450253023594434
   PubMedGoogle Scholar
• LaPorteSLJuoZSVaclavikovaJMolecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 systemCell2008132225927218243101
   PubMed Web of Science ®Google Scholar
• BeharMBarkenDWernerSLHoffmannAThe dynamics of signaling as a pharmacological targetCell2013155244846124120141
   PubMed Web of Science ®Google Scholar
• LangBTWangJFilousARAuNPMaCHShenYPleiotropic molecules in axon regeneration and neuroinflammationExp Neurol2014258172325017884
   PubMed Web of Science ®Google Scholar
• FangZTangYFangJSimvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathwayPLoS One201385e6282323690956
   PubMed Web of Science ®Google Scholar
• AgostiniMAlmeidaLYBastosDCThe fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomasMol Cancer Ther201413358559524362464
   PubMed Web of Science ®Google Scholar
• HiroshimaYMaawyAHassaneinMKThe tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acidPLoS One201498e10338225116261
   PubMed Web of Science ®Google Scholar
• HuangLWongCCMackenzieGGPhospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stressBMC Cancer20141414124575839
   PubMed Web of Science ®Google Scholar
• BowersLWMaximoIXBrennerAJNSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactionsCancer Res201474164446445725125682
   PubMed Web of Science ®Google Scholar
• AhmadABanerjeeSWangZKongDMajumdarAPSarkarFHAging and inflammation: etiological culprits of cancerCurr Aging Sci20092317418619997527
   PubMedGoogle Scholar
• DjansugurovaLBPerfilyevaAVZhunusovaGSDjantaevaKBIksanOAKhussainovaEMThe determination of genetic markers of age-related cancer pathologies in populations from KazakhstanFront Genet201347023675381
   PubMedGoogle Scholar
• GibsonTMMortonLMShielsMSClarkeCAEngelsEARisk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based studyAIDS201428152313231825111081
   PubMedGoogle Scholar
• NelwanEJPramonoLALubisAMDjoerbanZKaposi sarcoma of the eye in an HIV patient well-responded to HAARTActa Med Indones201446325325525348189
   PubMedGoogle Scholar
• HiľovskáLJendželovskýRFedoročkoPPotency of non-steroidal anti-inflammatory drugs in chemotherapyMol Clin Oncol20153131225469262
   PubMed Web of Science ®Google Scholar
• KarnezisTShayanRFoxSAchenMGStackerSAThe connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathwayOncotarget20123889390623097685
   PubMed Web of Science ®Google Scholar
• BaigentCPatronoCSelective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisalArthritis Rheum2003481122012528099
   PubMed Web of Science ®Google Scholar
• LynchMEWatsonCPThe pharmacotherapy of chronic pain: a reviewPain Res Manag2006111113816511612
   PubMedGoogle Scholar
• ChouRHuffmanLHMedications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guidelineAnn Intern Med2007147750551417909211
   PubMed Web of Science ®Google Scholar
• BujoldERobergeSLacasseYPrevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysisObstet Gynecol20101162 Pt 140241420664402
   PubMed Web of Science ®Google Scholar
• FloydCNFerroAMechanisms of aspirin resistancePharmacol Ther20141411697823993980
   PubMed Web of Science ®Google Scholar
• BachertCChuchalinAGEisebittRNetayzhenkoVZVoelkerMAspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging studyClin Ther2005277993100316154478
   PubMed Web of Science ®Google Scholar
• ParkSLeeNRLeeKEParkJYKimYJGwakHSEffects of single-nucleotide polymorphisms of FMO3 and FMO6 genes on pharmacokinetic characteristics of sulindac sulfide in premature laborDrug Metab Dispos2014421404324173915
   PubMed Web of Science ®Google Scholar
• BrownJRDuBoisRNCOX-2: a molecular target for colorectal cancer preventionJ Clin Oncol200523122840285515837998
   PubMed Web of Science ®Google Scholar
• HarrisREBeebe-DonkJDossHBurr DossDAspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockadeOncol Rep200513455958315756426
   PubMed Web of Science ®Google Scholar
• GhoshNChakiRMandalVMandalSCCOX-2 as a target for cancer chemotherapyPharmacol Rep201062223324420508278
   PubMed Web of Science ®Google Scholar
• SonoshitaMTakakuKSasakiNAcceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(delta 716) knockout miceNat Med2001791048105111533709
   PubMed Web of Science ®Google Scholar
• Hansen-PetrikMBMcEnteeMFJullBShiHZemelMBWhelanJProstaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) miceCancer Res200262240340811809688
   PubMed Web of Science ®Google Scholar
• HullMAKoSCHawcroftGProstaglandin EP receptors: targets for treatment and prevention of colorectal cancer?Mol Cancer Ther2004381031103915299086
   PubMed Web of Science ®Google Scholar
• HidaTYatabeYAchiwaHIncreased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomasCancer Res19985817376137649731479
   PubMed Web of Science ®Google Scholar
• LiuCHChangSHNarkoKOverexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic miceJ Biol Chem200127621185631856911278747
   PubMed Web of Science ®Google Scholar
• ChangSHAiYBreyerRMLaneTFHlaTThe prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasiaCancer Res200565114496449915930264
   PubMed Web of Science ®Google Scholar
• MazharDAngRWaxmanJCOX inhibitors and breast cancerBr J Cancer200694334635016421592
   PubMed Web of Science ®Google Scholar
• IshizakiTKatsumataKTsuchidaAEtodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activityInt J Mol Med200617235736216391837
   PubMed Web of Science ®Google Scholar
• IwataCKanoMRKomuroAInhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesisCancer Res20076721101811018917974958
   PubMed Web of Science ®Google Scholar
• KarnezisTShayanRCaesarCVEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endotheliumCancer Cell201221218119522340592
   PubMed Web of Science ®Google Scholar
• DongXLiRXiuPMeloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2-dependent and -independent pathwaysPLoS One201493e9286424675684
   PubMed Web of Science ®Google Scholar
• NaruseTNishidaYHosonoKIshiguroNMeloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routesCarcinogenesis200627358459216219634
   PubMed Web of Science ®Google Scholar
• GuptaRADuboisRNColorectal cancer prevention and treatment by inhibition of cyclooxygenase-2Nat Rev Cancer200111112111900248
   PubMed Web of Science ®Google Scholar
• HarrisREBeebe-DonkJSchullerHMChemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokersOncol Rep20029469369512066194
   PubMed Web of Science ®Google Scholar
• MuranushiCOlsenCMPandeyaNGreenACAspirin and non-steroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysisJ Invest Dermatol2014135497598325521453
   PubMed Web of Science ®Google Scholar
• WongCCChengKWRigasBPreclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agentsJ Pharmacol Exp Ther2012341357257822448039
   PubMed Web of Science ®Google Scholar
• MatosPKotelevetsLGonçalvesVIbuprofen inhibits colitis-induced overexpression of tumor-related Rac1bNeoplasia201315110211123359345
   PubMed Web of Science ®Google Scholar
• SuBXuBWanJCorrelation between long-term aspirin use and F-fluorodeoxyglucose uptake in colorectal cancer measured by PET/CTPLoS One2014910e10945925290692
   PubMed Web of Science ®Google Scholar
• LiggettJLChoiCKDonnellRLNonsteroidal anti-inflammatory drug sulindac sulfide suppresses structural protein nesprin-2 expression in colorectal cancer cellsBiochim Biophys Acta20141840132233124080406
   PubMed Web of Science ®Google Scholar
• LiggettJLMinKWSmolenskyDBaekSJA novel COX-independent mechanism of sulindac sulfide involves cleavage of epithelial cell adhesion molecule proteinExp Cell Res201432611924859349
   PubMed Web of Science ®Google Scholar
• LiggettJLZhangXElingTEBaekSJAnti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targetsCancer Lett2014346221722424486220
   PubMed Web of Science ®Google Scholar
• VidalACHowardLEMoreiraDMCastro-SantamariaRAndrioleGLFreedlandSJAspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE studyClin Cancer Res201521475676225520389
   PubMed Web of Science ®Google Scholar
• ChanATAspirin and familial adenomatous polyposis: coming full circleCancer Prev Res (Phila)20114562362721543340
   PubMed Web of Science ®Google Scholar
• KimKYJeonSWParkJGRegression of colonic adenomas after treatment with sulindac in familial adenomatous polyposis: a case with a 2-year follow-up without a prophylactic colectomyAnn Coloproctol201430420120425210691
   PubMedGoogle Scholar
• XieGSunYNieTPhospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse modelsJ Pharmacol Exp Ther2011337387688621422165
   PubMed Web of Science ®Google Scholar
• ChengKWWongCCAlstonNAerosol administration of phospho-sulindac inhibits lung tumorigenesisMol Cancer Ther20131281417142823645590
   PubMed Web of Science ®Google Scholar
• HuangLWongCCChengKWRigasBPhospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effectPLoS One2014911e11172025369051
   PubMed Web of Science ®Google Scholar
• MukherjeeDNissenSETopolEJRisk of cardiovascular events associated with selective COX-2 inhibitorsJAMA2001286895495911509060
   PubMed Web of Science ®Google Scholar
• BresalierRSSandlerRSQuanHCardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trialN Engl J Med2005352111092110215713943
   PubMed Web of Science ®Google Scholar
• BaronJASandlerRSBresalierRSA randomized trial of rofecoxib for the chemoprevention of colorectal adenomasGastroenterology200613161674168217087947
   PubMed Web of Science ®Google Scholar
• FujimuraTOhtaTOyamaKMiyashitaTMiwaKCyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancersJ Gastrointest Cancer2007382–4788219031117
   PubMedGoogle Scholar
• LanasABaronJASandlerRSPeptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trialGastroenterology2007132249049717258718
   PubMed Web of Science ®Google Scholar
• PattersonSLColbert MaressoKHawkECancer chemoprevention: successes and failuresClin Chem20135919410123150056
   PubMed Web of Science ®Google Scholar
• CooperDLMurrellDEConderCMExacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in ratsPLoS One201492e8908724586517
   PubMed Web of Science ®Google Scholar
• KawasakiASuzukiKTakekawaHCo-occurrence of multiple cerebral infarctions due to hypercoagulability associated with malignancy and meningeal carcinomatosis as the initial manifestation of gastric cancerBMC Neurol20141416025103421
   PubMed Web of Science ®Google Scholar
• TianSHirshfieldKMJabbourSKSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsFront Oncol2014427725346912
   PubMedGoogle Scholar
• AurielERegevKKorczynADNonsteroidal anti-inflammatory drugs exposure and the central nervous systemHandb Clin Neurol201411957758424365321
   PubMedGoogle Scholar
• SaffRRBanerjiAManagement of patients with nonaspirin-exacerbated respiratory disease aspirin hypersensitivity reactionsAllergy Asthma Proc2015361343925562554
   PubMed Web of Science ®Google Scholar
• SiokaCKyritsisAPCentral and peripheral nervous system toxicity of common chemotherapeutic agentsCancer Chemother Pharmacol200963576176719034447
   PubMed Web of Science ®Google Scholar
• BruchimIGoldbergAFishmanAConfino-CohenRCarboplatin hypersensitivity: evaluation and successful desensitization protocolImmunotherapy20146890591225313569
   PubMed Web of Science ®Google Scholar
• BakSAndersenMTsiropoulosIRisk of stroke associated with non steroidal anti-inflammatory drugs: a nested case-control studyStroke200334237938612574546
   PubMed Web of Science ®Google Scholar
• CruzRJJrVincenziRKetzerBMCecilioALCepedaLASpontaneous intratumoral bleeding and rupture of giant gastric stromal tumor (>30 cm) in a young patientWorld J Surg Oncol200867618627622
   PubMed Web of Science ®Google Scholar
• KwonYAhnJSJeonSRIntratumoral bleeding in meningioma after gamma knife radiosurgeryJ Neurosurg2002975 SupplS657S662
   PubMedGoogle Scholar
• Lakshmi PrasadGRamdurgSRSuriAMahapatraAKA rare association of meningioma with intratumoral bleed and acute subdural hematomaNeurol India201058697797821150084
   PubMed Web of Science ®Google Scholar
• ChenWCLiYDChiangPHComparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort studyBiomed Res Int2014201469356725295267
   PubMed Web of Science ®Google Scholar
• BonelliPTuccilloFMFedericoAIbuprofen delivered by poly(lactic-co-glycolic acid) (PLGA) nanoparticles to human gastric cancer cells exerts antiproliferative activity at very low concentrationsInt J Nanomedicine201275683569123180963
   PubMed Web of Science ®Google Scholar
• MouradJJThe evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential targetVasc Health Risk Manag2008461315132519337545
   PubMedGoogle Scholar
• KalaitzidisRGBakrisGLThe current state of RAAS blockade in the treatment of hypertension and proteinuriaCurr Cardiol Rep200911643644219863868
   PubMedGoogle Scholar
• VajapeyRRiniDWalstonJAbadirPThe impact of age-related dysregulation of the angiotensin system on mitochondrial redox balanceFront Physiol2014543925505418
   PubMed Web of Science ®Google Scholar
• SchwedaFSalt feedback on the renin-angiotensin-aldosterone systemPflugers Arch2014467356557625502115
   PubMed Web of Science ®Google Scholar
• TamaratRSilvestreJSDurieMLevyBIAngiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathwaysLab Invest200282674775612065685
   PubMed Web of Science ®Google Scholar
• AgerEINeoJChristophiCThe renin-angiotensin system and malignancyCarcinogenesis20082991675168418632755
   PubMed Web of Science ®Google Scholar
• ArrietaOGuevaraPEscobarEGarcía-NavarreteRPinedaBSoteloJBlockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat gliomaBr J Cancer20059271247125215785746
   PubMed Web of Science ®Google Scholar
• SuganumaTInoKShibataKFunctional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal disseminationClin Cancer Res20051172686269415814650
   PubMed Web of Science ®Google Scholar
• MiyajimaAKikuchiEKosakaTOyaMAngiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancerRev Recent Clin Trials200942757819463103
   PubMedGoogle Scholar
• WasaJSugiuraHKozawaEKohyamaKYamadaKTaguchiOThe tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma modelAnticancer Res201131112312721273589
   PubMed Web of Science ®Google Scholar
• ShirotakeSMiyajimaAKosakaTRegulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancerAm J Pathol201218031008101622226738
   PubMed Web of Science ®Google Scholar
• UemuraHNakaigawaNIshiguroHKubotaYAntiproliferative efficacy of angiotensin II receptor blockers in prostate cancerCurr Cancer Drug Targets20055530732316101380
   PubMed Web of Science ®Google Scholar
• UemuraHIshiguroHKubotaYPharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatmentInt J Urol2008151192618184167
   PubMed Web of Science ®Google Scholar
• IzzedineHEderhySGoldwasserFManagement of hypertension in angiogenesis inhibitor-treated patientsAnn Oncol200920580781519150949
   PubMed Web of Science ®Google Scholar
• MasamuneAHamadaSKikutaKThe angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in miceScand J Gastroenterol201348560260923477656
   PubMed Web of Science ®Google Scholar
• WilsonJSPirolaRCApteMVStars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progressionFront Physiol201455224592240
   PubMed Web of Science ®Google Scholar
• KosakaTMiyajimaATakayamaEAngiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancerProstate2007671414917044086
   PubMed Web of Science ®Google Scholar
• KosugiMMiyajimaAKikuchiEHoriguchiYMuraiMAngiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancerClin Cancer Res20061292888289316675585
   PubMed Web of Science ®Google Scholar
• AlhusbanAAl-AzayzihAGocAGaoFFaganSCSomanathPRClinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesisJ Pharmacol Exp Ther2014350363564524990940
   PubMed Web of Science ®Google Scholar
• OkazakiMFushidaSHaradaSThe angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancerCancer Lett20143551465325224569
   PubMed Web of Science ®Google Scholar
• RiveraEArrietaOGuevaraPDuarte-RojoASoteloJAT1 receptor is present in glioma cells; its blockage reduces the growth of rat gliomaBr J Cancer20018591396139911720480
   PubMed Web of Science ®Google Scholar
• ParkYAChoiCHDoIGDual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinomaGynecol Oncol2014135110811725014541
   PubMed Web of Science ®Google Scholar
• ChoiCHParkYAChoiJJAngiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cellsGynecol Oncol2012126112413122525818
   PubMed Web of Science ®Google Scholar
• Diop-FrimpongBChauhanVPKraneSBoucherYJainRKLosartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumorsProc Natl Acad Sci U S A201110872909291421282607
   PubMed Web of Science ®Google Scholar
• FunaoKMatsuyamaMKawahitoYTelmisartan is a potent target for prevention and treatment in human prostate cancerOncol Rep200820229530018636189
   PubMed Web of Science ®Google Scholar
• OzekiKTanidaSMorimotoCTelmisartan inhibits cell proliferation by blocking nuclear translocation of ProHB-EGF C-terminal fragment in colon cancer cellsPLoS One201382e5677023451083
   PubMed Web of Science ®Google Scholar
• NakagawaTKubotaTKabutoMKoderaTCaptopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinasesAnticancer Res1995155B198199
   Web of Science ®Google Scholar
• WilliamsRNParsonsSLMorrisTMRowlandsBJWatsonSAInhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine modelsEur J Surg Oncol20053191042105015993560
   PubMed Web of Science ®Google Scholar
• AttoubSGabenAMAl-SalamSCaptopril as a potential inhibitor of lung tumor growth and metastasisAnn N Y Acad Sci20081138657218837885
   PubMed Web of Science ®Google Scholar
• VolpertOVWardWFLingenMWCaptopril inhibits angiogenesis and slows the growth of experimental tumors in ratsJ Clin Invest19969836716798698858
   PubMed Web of Science ®Google Scholar
• de Groot-BesselingRRRuersTJvan KraatsAAAnti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft modelInt J Cancer2004112232933415352048
   PubMed Web of Science ®Google Scholar
• MiyajimaAAsanoTHayakawaMCaptopril restores transforming growth factor-beta type II receptor and sensitivity to transforming growth factor-beta in murine renal cell cancer cellsJ Urol2001165261662011176447
   PubMed Web of Science ®Google Scholar
• HiiSINicolDLGotleyDCThompsonLCGreenMKJonssonJRCaptopril inhibits tumour growth in a xenograft model of human renal cell carcinomaBr J Cancer19987768808839528828
   PubMed Web of Science ®Google Scholar
• SmallWJrMolteniAKimYTTaylorJMChenZWardWFCaptopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in cultureBreast Cancer Res Treat19974432172249266101
   PubMed Web of Science ®Google Scholar
• KohSLAgerEICostaPLMalcontenti-WilsonCMuralidharanVChristophiCBlockade of the renin-angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liverClin Exp Metastasis2014314395405
   PubMed Web of Science ®Google Scholar
• KastREKarpel-MasslerGHalatschMECUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomideOncotarget20145188052808225211298
   PubMed Web of Science ®Google Scholar
• ReddyMKBaskaranKMolteniAInhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cellsProc Soc Exp Biol Med199521032212268539259
   PubMed Web of Science ®Google Scholar
• YoshijiHKuriyamaSKawataMThe angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factorClin Cancer Res2001741073107811309359
   PubMed Web of Science ®Google Scholar
• YoshijiHKuriyamaSFukuiHPerindopril: possible use in cancer therapyAnticancer Drugs200213322122811984065
   PubMed Web of Science ®Google Scholar
• OgilvieRIAnandSRoyPDe SouzaSPerindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based studyClin Drug Investig20082811673686
   PubMed Web of Science ®Google Scholar
• NoguchiRYoshijiHKuriyamaSCombination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesisClin Cancer Res2003916 Pt 16038604514676130
   PubMed Web of Science ®Google Scholar
• YoshijiHNoguchiRKuriyamaSYoshiiJIkenakaYCombination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in miceOncol Rep200513349149515706423
   PubMed Web of Science ®Google Scholar
• YoshijiHKuriyamaSNoguchiRCombination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppressionJ Hepatol200542568769315826718
   PubMed Web of Science ®Google Scholar
• YasumatsuRNakashimaTMasudaMEffects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cellsJ Cancer Res Clin Oncol20041301056757315449186
   PubMed Web of Science ®Google Scholar
• UemuraHHasumiHKawaharaTPilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancerInt J Clin Oncol200510640541016369744
   PubMedGoogle Scholar
• WilopSvon HobeSCrysandtMEsserAOsiekaRJostEImpact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapyCancer Res Clin Oncol20091351014291435
   PubMed Web of Science ®Google Scholar
• TatokoroMFujiiYKawakamiSPhase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinomaCancer Sci2011102113714320973869
   PubMed Web of Science ®Google Scholar
• NakaiYIsayamaHIjichiHPhase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1Cancer Sci201210381489149222515232
   PubMed Web of Science ®Google Scholar
• NakaiYIsayamaHIjichiHA multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2Invest New Drugs20133151294129923690239
   PubMed Web of Science ®Google Scholar
• van der KnaapRSiemesCCoeberghJWvan DuijnCMHofmanAStrickerBHRenin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam StudyCancer2008112474875718181094
   PubMed Web of Science ®Google Scholar
• SiragyHMA current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitorsVasc Health Risk Manag2011729731321633727
   PubMedGoogle Scholar
• LundeHHednerTSamuelssonODyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitorsBMJ1994308692018218298346
   PubMed Web of Science ®Google Scholar
• TschöpeCSchultheissHPWaltherTMultiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockadeJ Cardiovasc Pharmacol200239447848711904521
   PubMed Web of Science ®Google Scholar
• DicpinigaitisPVAngiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelinesChest20061291 SupplS169S173
   PubMed Web of Science ®Google Scholar
• StoneCAKennyRANolanBLawlorPGAutonomic dysfunction in patients with advanced cancer; prevalence, clinical correlates and challenges in assessmentBMC Palliat Care201211322379978
   PubMed Web of Science ®Google Scholar
• LissoniPPittalisSArdizzoiaAPrevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatoninSupport Care Cancer1996443133168829312
   PubMed Web of Science ®Google Scholar
• SelcukbiricikFTuralDSenelTESarıcaASoylukOSerdengectiSBilateral ischemic optic neuropathy developed under interferon therapyCase Rep Ophthalmol Med2012201210273923119208
   PubMedGoogle Scholar
• GuillemPPapachristosIPeillonCTribouletJPEtilefrine use in the management of post-operative chyle leaks in thoracic surgeryInteract Cardiovasc Thorac Surg20043115616017670203
   PubMedGoogle Scholar
• KranzfelderMGertlerRHapfelmeierAFriessHFeithMChylothorax after esophagectomy for cancer: impact of the surgical approach and neoadjuvant treatment: systematic review and institutional analysisSurg Endosc201327103530353823708712
   PubMed Web of Science ®Google Scholar
• PokornáJMachalaLRezáčováPKonvalinkaJCurrent and novel inhibitors of HIV proteaseViruses2009131209123921994591
   PubMed Web of Science ®Google Scholar
• BrikAWongCHHIV-1 protease: mechanism and drug discoveryOrg Biomol Chem20031151412929379
   PubMed Web of Science ®Google Scholar
• PerryCMFramptonJEMcCormackPLSiddiquiMACvetkovićRSNelfinavir: a review of its use in the management of HIV infectionDrugs200565152209224416225378
   PubMed Web of Science ®Google Scholar
• MoniniPSgadariCBarillariGEnsoliBHIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activityJ Antimicrob Chemother200351220721112562682
   PubMed Web of Science ®Google Scholar
• SgadariCBarillariGToschiEHIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcomaNat Med20028322523211875492
   PubMed Web of Science ®Google Scholar
• ChowWAJiangCGuanMAnti-HIV drugs for cancer therapeutics: back to the future?Lancet Oncol2009101617119111246
   PubMed Web of Science ®Google Scholar
• GillsJJLopiccoloJTsurutaniJNelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivoClin Cancer Res200713175183519417785575
   PubMed Web of Science ®Google Scholar
• YangYIkezoeTTakeuchiTHIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signalingCancer Sci200596742543316053514
   PubMed Web of Science ®Google Scholar
• YangYIkezoeTNishiokaCNFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell linesBr J Cancer200695121653166217133272
   PubMed Web of Science ®Google Scholar
• GuanMFousekKChowWANelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancerFEBS J2012279132399241122540830
   PubMed Web of Science ®Google Scholar
• GuanMFousekKJiangCNelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6Clin Cancer Res20111771796180621355074
   PubMed Web of Science ®Google Scholar
• BonoCKarlinLHarelSThe human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivoHaematologica20129771101110922271897
   PubMed Web of Science ®Google Scholar
• KastREHalatschMEMatrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs – captopril, disulfiram and nelfinavir – are inhibitors with potential as adjunctive treatments in glioblastomaArch Med Res201243324324722564423
   PubMed Web of Science ®Google Scholar
• JiangWMikochikPJRaJHHIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrestCancer Res20076731221122717283158
   PubMed Web of Science ®Google Scholar
• BrüningABurgerPVogelMNelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosisCancer Biol Ther20098322623219106637
   PubMed Web of Science ®Google Scholar
• PoreNGuptaAKCernigliaGJNelfinavir down-regulates hypoxia-inducible factor 1 alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapyCancer Res200666189252925916982770
   PubMed Web of Science ®Google Scholar
• SrirangamAMitraRWangMEffects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancerClin Cancer Res20061261883189616551874
   PubMed Web of Science ®Google Scholar
• KumarSBryantCSChamalaSRitonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cellsMol Cancer200982619386116
   PubMed Web of Science ®Google Scholar
• McLeanKVanDeVenNASorensonDRDaudiSLiuJRThe HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cellsGynecol Oncol2009112362363019147209
   PubMed Web of Science ®Google Scholar
• ViciPMarianiLPizzutiLEmerging biological treatments for uterine cervical carcinomaJ Cancer201452869724494026
   PubMed Web of Science ®Google Scholar
• GanttSCasperCAmbinderRFInsights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and preventionCurr Opin Oncol201325549550223872785
   PubMed Web of Science ®Google Scholar
• ZhangRLuoDMiaoRHsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosisOncogene200524243954396315782121
   PubMed Web of Science ®Google Scholar
• PyrkoPKardoshAWangWXiongWSchönthalAHChenTCHIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stressCancer Res20076722109201092818006837
   PubMed Web of Science ®Google Scholar
• ZhangKKaufmanRJSignaling the unfolded protein response from the endoplasmic reticulumJ Biol Chem200427925259352593815070890
   PubMed Web of Science ®Google Scholar
• PajonkFHimmelsbachJRiessKSommerAMcBrideWHThe human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cellsCancer Res200262185230523512234989
   PubMed Web of Science ®Google Scholar
• BrunnerTBGeigerMGrabenbauerGGPhase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancerJ Clin Oncol200826162699270618509182
   PubMed Web of Science ®Google Scholar
• Alonso-BasantaMFangPMaityAHahnSMLustigRADorseyJFA phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiformeJ Neurooncol2014116236537224194293
   PubMed Web of Science ®Google Scholar
• BlumenthalGMGillsJJBallasMSA phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumorsOncotarget20145188161817225327558
   PubMedGoogle Scholar
• BuijsenJLammeringGJansenRLPhase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancerRadiother Oncol2013107218418823647753
   PubMed Web of Science ®Google Scholar
• RenganRMickRPrymaDA phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical responseJ Thorac Oncol20127470971522425919
   PubMed Web of Science ®Google Scholar
• HooverACMilhemMMAndersonCMEfficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: results of a phase II clinical trialHead Neck Epub201435
   PubMed Web of Science ®Google Scholar
• PenzakSRChuckSKManagement of protease inhibitor-associated hyperlipidemiaAm J Cardiovasc Drugs2002229110614727985
   PubMedGoogle Scholar
• CalzaLManfrediRChiodoFUse of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAARTInfection2002301263111876511
   PubMed Web of Science ®Google Scholar
• KalraSKalraBAgrawalNUnnikrishnanAUnderstanding diabetes in patients with HIV/AIDSDiabetol Metab Syndr201131221232158
   PubMed Web of Science ®Google Scholar
• GillsJJLopiccoloJDennisPANelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagyAutophagy20084110710918000394
   PubMed Web of Science ®Google Scholar
• YogasundaramHPutkoBNTienJHydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatmentCan J Cardiol201430121706171525475472
   PubMed Web of Science ®Google Scholar
• RahimRStroblJSHydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cellsAnticancer Drugs200920873674519584707
   PubMed Web of Science ®Google Scholar
• BrüningAGingelmaierAFrieseKMylonasINew prospects for nelfinavir in non-HIV-related diseasesCurr Mol Pharmacol201032919720359290
   PubMedGoogle Scholar
• PadhyBMGuptaYKDrug repositioning: re-investigating existing drugs for new therapeutic indicationsJ Postgrad Med201157215316021654146
   PubMed Web of Science ®Google Scholar
• SchneiderBPLiLShenFGenetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100Br J Cancer201411161241124825117820
   PubMed Web of Science ®Google Scholar